Table 1 Patient characteristics and treatment
From: Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Characteristic | IR RT alone (n = 177) | IR RT+ ADT (n = 196) | P |
|---|---|---|---|
Age (mean ± SD, years) | 72 ± 5.34 | 72 ± 5.85 | 0.934 |
Pretreatment PSA (ng/mL) | 7.88 ± 3.55 | 9.34 ± 3.97 | 0.001> |
Fiducials implant % (n) | 71.8 (127) | 65.3 (128) | 0.181 |
Gleason score % (n) | 0.257 | ||
5 or 6 | 19.8 (35) | 15.8 (31) | |
7 (3 + 4) | 52.5 (93) | 49.0 (96) | |
7 (4 + 3) | 27.7 (49) | 35.2 (69) | |
T- stage % (n) | 0.074 | ||
T1 | 31.4 (50) | 23.4 (37) | |
T2a-b | 64.8 (103) | 67.7 (107) | |
T2c | 3.8 (6) | 8.9 (14) | |
No. IR risk factors % (n) | 0.001> | ||
1 | 65.0 (115) | 42.6 (83) | |
2 | 31.1 (55) | 48.7 (95) | |
3 | 4.0 (7) | 8.7 (17) | |
RT treatment modality % (n) | 0.929 | ||
3D | 17.2 (29) | 15.7 (29) | |
IMRT | 23.1 (39) | 23.8 (44) | |
VMAT | 59.8 (101) | 60.5 (112) | |
RT lymph-nodes % (n) | 2.8 (5) | 10.7 (21) | 0.003 |
Positive biopsy cores % (mean ± SD) | 45.33 ± 25.56 | 52.56 ± 27.61 | 0.017 |
Charlson comorbidity index | 0.774 | ||
2 | 49.4 (80) | 52.0 (93) | |
3 | 16.7 (27) | 14.0 (25) | |
4≤ | 34.0 (55) | 34.1 (61) | |
Months follow-up | 57.6 ± 36.9 | 54.3 ± 37.4 | 0.383 |